The evidence that COPZ1 knockdown kills both proliferating and non-dividing tumor cells, but spares normal cells, suggested the potential of COPZ1-targeting therapies to selectively eradicate cancer cells, independently of their proliferative status. Here, COPZ1 is linked to neoplasm.